How do you sequence therapy for metastatic NSCLC patient with a BRAF V600E mutation?

In a newly diagnosed patient with metastatic NSCLC that harbors a BRAF V600E mutation, my preferred first line therapy is the combination of Dabrafenib plus Trametinib. My recommendation is based upon the high response rate (65%) of this combination observed in phase II trials. I would inform the pa...